Reports Q1 revenue $367.7M, consensus $316.3M. “We had an excellent start to the year, driving robust volume, revenue and margin growth and achieving cash flow breakeven earlier than expected,” said Steve Chapman, chief executive officer of Natera. “We continued to deliver on our mission to transform disease management with the launch of a highly differentiated product in women’s health and the publication of practice-changing data in oncology and organ health.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Baird says FDA final LDT rule favorable for Life Sciences, Diagnostics coverage
- TipRanks’ ‘Perfect 10’ List: Analysts See Opportunity in These 2 Top-Scoring Stocks
- Natera announces publication of dd-cfDNA study data
- Natera assumed with a Buy at Craig-Hallum
- Natera announces new data from two studies on Prospera Heart dd-cfDNA test
